IMVT insider transaction filings
Immunovant, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-21. Screen IMVT transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-21 | 4 | Gloria Melanie — Chief Operating Officer | Sale (S): 3,056 @ $44.16 | EDGAR |
| 2026-07-24 | 4 | Stout Jay S — Chief Technology Officer | Sale (S): 2,857 @ $38.69 | EDGAR |
| 2026-07-24 | 4 | Girao Tiago — Chief Financial Officer | Sale (S): 6,798 @ $38.69 | EDGAR |
| 2026-07-24 | 4 | Pande Atul — Director | Option exercise (M): 1,500 @ $8.43 · Sale (S): 1,500 @ $39.80 · Option exercise (M): 1,500 (derivative) @ $0 | EDGAR |
| 2026-07-10 | 4 | Gloria Melanie — Chief Operating Officer | Sale (S): 1,930 @ $39.53 · Sale (S): 106 @ $39.99 | EDGAR |
| 2026-07-10 | 4 | Van Tuyl Christopher — Chief Legal Officer | Sale (S): 1,143 @ $39.53 · Sale (S): 63 @ $39.99 | EDGAR |
| 2026-07-10 | 4 | Stout Jay S — Chief Technology Officer | Sale (S): 1,906 @ $39.53 · Sale (S): 105 @ $39.99 · Sale (S): 1,399 @ $39.53 · Sale (S): 77 @ $39.99 | EDGAR |
| 2026-07-06 | 4 | Venker Eric — Chief Executive Officer, Director | Option exercise (M): 92,188 @ $14.46 · Disposition to issuer (D): 86,629 @ $38.14 · Sale (S): 3,092 @ $38.48 · Option exercise (M): 92,188 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Gloria Melanie — Chief Operating Officer | Sale (S): 14,748 @ $38.18 · Sale (S): 2,966 @ $38.95 | EDGAR |
| 2026-06-26 | 4 | Van Tuyl Christopher — Chief Legal Officer | Option exercise (M): 17,824 @ $15.20 · Sale (S): 14,982 @ $38.19 · Sale (S): 2,842 @ $38.96 · Option exercise (M): 17,824 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Stout Jay S — Chief Technology Officer | Sale (S): 33,277 @ $38.18 · Sale (S): 6,723 @ $38.94 | EDGAR |
| 2026-06-26 | 4 | Pande Atul — Director | Option exercise (M): 1,500 @ $8.43 · Sale (S): 1,500 @ $38.01 · Option exercise (M): 1,500 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Girao Tiago — Chief Financial Officer | Option exercise (M): 10,000 @ $15.90 · Sale (S): 10,000 @ $38.46 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Van Tuyl Christopher — Chief Legal Officer | Sale (S): 2,634 @ $35.39 | EDGAR |
| 2026-06-16 | 4 | Pande Atul — Director | Option exercise (M): 1,500 @ $8.43 · Sale (S): 1,500 @ $34.02 · Option exercise (M): 1,500 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Fromkin Andrew J. — Director | Option exercise (M): 31,668 @ $4.99 · Option exercise (M): 71,492 @ $7.94 · Option exercise (M): 77,181 @ $8.43 · Option exercise (M): 16,260 @ $14.70 · Sale (S): 11,483 @ $32.64 · Sale (S): 210,468 @ $33.56 · +4 more | EDGAR |
| 2026-05-22 | 4 | Gloria Melanie — Chief Operating Officer | Sale (S): 249 @ $30.41 · Sale (S): 1,168 @ $32.15 · Sale (S): 1,698 @ $32.95 | EDGAR |
| 2026-05-20 | 4 | Pande Atul — Director | Option exercise (M): 6,000 @ $8.43 · Sale (S): 6,000 @ $32 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Susman Robert Graham — Director | Sale (S): 2,502 @ $27.17 | EDGAR |
| 2026-04-24 | 4 | Stout Jay S — Chief Technology Officer | Sale (S): 2,754 @ $29.62 | EDGAR |
| 2026-04-24 | 4 | Girao Tiago — Chief Financial Officer | Sale (S): 25,760 @ $29.62 | EDGAR |
| 2026-04-10 | 4 | Gloria Melanie — Chief Operating Officer | Sale (S): 8,722 @ $24.83 | EDGAR |
| 2026-04-10 | 4 | Van Tuyl Christopher — Chief Legal Officer | Sale (S): 5,165 @ $24.83 | EDGAR |
| 2026-04-10 | 4 | Stout Jay S — Chief Technology Officer | Sale (S): 8,614 @ $24.83 · Sale (S): 1,518 @ $24.83 | EDGAR |
| 2026-04-09 | 4 | Susman Robert Graham — Director | Grant/award (A): 13,880 @ $0 · Grant/award (A): 7,061 (derivative) @ $0 | EDGAR |
| 2026-04-09 | 4 | Gloria Melanie — Chief Operating Officer | Grant/award (A): 83,671 @ $0 · Grant/award (A): 121,063 (derivative) @ $0 | EDGAR |
| 2026-04-09 | 4 | Van Tuyl Christopher — Chief Legal Officer | Grant/award (A): 41,343 @ $0 · Grant/award (A): 59,820 (derivative) @ $0 | EDGAR |
| 2026-04-09 | 4 | Venker Eric — Chief Executive Officer, Director | Grant/award (A): 232,252 @ $0 · Grant/award (A): 336,043 (derivative) @ $0 | EDGAR |
| 2026-04-09 | 4 | Hughes Douglas J. — Director | Grant/award (A): 13,880 @ $0 · Grant/award (A): 7,061 (derivative) @ $0 | EDGAR |
| 2026-04-09 | 4 | Stout Jay S — Chief Technology Officer | Grant/award (A): 66,937 @ $0 · Grant/award (A): 96,851 (derivative) @ $0 | EDGAR |
| 2026-04-09 | 4 | Bauer Jake — Director | Grant/award (A): 13,880 @ $0 · Grant/award (A): 7,061 (derivative) @ $0 | EDGAR |
| 2026-04-09 | 4 | Torti Frank — Director | Grant/award (A): 174,189 @ $0 · Grant/award (A): 88,325 (derivative) @ $0 | EDGAR |
| 2026-04-09 | 4 | Pande Atul — Director | Grant/award (A): 13,880 @ $0 · Grant/award (A): 7,061 (derivative) @ $0 | EDGAR |
| 2026-04-09 | 4 | Girao Tiago — Chief Financial Officer | Grant/award (A): 64,968 @ $0 · Grant/award (A): 94,002 (derivative) @ $0 | EDGAR |
| 2026-04-09 | 4 | Fromkin Andrew J. — Director | Grant/award (A): 13,880 @ $0 · Grant/award (A): 7,061 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Venker Eric — Chief Executive Officer, Director | Option exercise (M): 368,750 @ $14.46 · Disposition to issuer (D): 334,960 @ $25.10 · Sale (S): 12,820 @ $24.04 · Sale (S): 1,409 @ $24.60 · Option exercise (M): 368,750 (derivative) @ $0 | EDGAR |
| 2026-03-20 | 4 | Van Tuyl Christopher — Chief Legal Officer | Sale (S): 2,877 @ $24.97 | EDGAR |
| 2026-02-27 | 4 | Gloria Melanie — Chief Operating Officer | Sale (S): 1,437 @ $26.98 · Sale (S): 859 @ $28.16 · Sale (S): 942 @ $28.90 | EDGAR |
| 2026-01-23 | 4 | Stout Jay S — Chief Technology Officer | Sale (S): 1,977 @ $26.03 | EDGAR |
| 2026-01-09 | 4 | Stout Jay S — Chief Technology Officer | Sale (S): 1,148 @ $26.51 · Sale (S): 55 @ $26.92 | EDGAR |
| 2025-12-19 | 4 | Van Tuyl Christopher — Chief Legal Officer | Sale (S): 8,529 @ $26.78 · Sale (S): 2,284 @ $27.38 | EDGAR |
| 2025-12-12 | 4 | Roivant Sciences Ltd. — Director, 10% owner | Purchase (P): 16,666,666 @ $21 | EDGAR |
| 2025-12-03 | 4 | Hughes Douglas J. — Director | Sale (S): 13,091 @ $23.14 · Sale (S): 1,909 @ $23.96 | EDGAR |
| 2025-12-03 | 4 | Fromkin Andrew J. — Director | Sale (S): 19,351 @ $23.14 · Sale (S): 2,898 @ $23.95 | EDGAR |
| 2025-11-21 | 4 | Gloria Melanie — Chief Operating Officer | Sale (S): 10,251 @ $23.54 · Sale (S): 2,375 @ $23.97 | EDGAR |
| 2025-10-24 | 4 | Geffner Michael — Chief Medical Officer | Sale (S): 2,595 @ $19.03 | EDGAR |
| 2025-10-24 | 4 | Stout Jay S — Chief Technology Officer | Sale (S): 2,520 @ $19.03 | EDGAR |
| 2025-10-10 | 4 | Geffner Michael — Chief Medical Officer | Sale (S): 1,272 @ $16.30 | EDGAR |
| 2025-10-10 | 4 | Stout Jay S — Chief Technology Officer | Sale (S): 1,585 @ $16.30 | EDGAR |
| 2025-07-30 | 4 | Venker Eric — Chief Executive Officer, Director | Grant/award (A): 1,300,000 (derivative) @ $0 · Grant/award (A): 189,900 (derivative) @ $0 · Grant/award (A): 1,475,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Immunovant, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-20 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-12 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-11 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-11-21 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-11-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-03 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-28 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=IMVT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →